By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Newron Pharmaceuticals 

Via R. Lepetit
21040
Gerenzano      Italy
Phone: 39-02-9668131 Fax: 39-02-96681333


SEARCH JOBS


Industry
Pharmaceutical






Company News
Newron Pharmaceuticals (NWRN) To Present At The 17th Annual BIO CEO & Investor Conference And The Leerink Global Healthcare Conference 2/6/2015 12:00:35 PM
Newron Pharmaceuticals (NWRN) Initiates Phase 2 Study Of sNN0029 In Patients With Amyotrophic Lateral Sclerosis 1/16/2015 3:03:53 PM
Newron Pharmaceuticals (NWRN) Announces Results Of Phase I Study Of NW-3509 Phase II Study In Schizophrenia Patients Planned For Q2 2015 1/15/2015 8:55:25 AM
Newron Pharmaceuticals (NWRN) Initiates Phase 2 Study Of sNN0031 In Patients With Parkinson’s disease 1/14/2015 9:18:52 AM
Newron Pharmaceuticals (NWRN) Release: CHMP Recommends Approval Of Xadago™ (Safinamide) To Treat Parkinson's Disease In The EU 1/7/2015 8:33:41 AM
Newron Pharmaceuticals (NWRN) Release: Safinamide New Drug Application (NDA) Re-Submitted To The US FDA 12/29/2014 7:34:19 AM
Newron Pharmaceuticals (NWRN) Reports Half-Year Results 2014 9/16/2014 11:19:03 AM
Newron Pharmaceuticals (NWRN) Shares To Be Included In The SXI Life Sciences® And The SXI Bio+Medtech® Indices 7/11/2014 8:40:08 AM
Newron Pharmaceuticals (NWRN) Establishes U.S. Operations 7/8/2014 9:03:09 AM
Newron Pharmaceuticals (NWRN) Release: Safinamide New Drug Application Submitted To The FDA 5/29/2014 10:49:38 AM
123456789
//-->